considerations to optimize the outcomes of bispecific antibody treatment in patients with myeloma
Published 9 months ago • 75 plays • Length 1:01Download video MP4
Download video MP3
Similar videos
-
4:00
optimizing the outcomes of autohsct in multiple myeloma
-
2:06
improving treatment access with off-the-shelf bispecific antibodies in multiple myeloma
-
6:15
how to manage and report aes associated with bispecific antibody treatment in myeloma
-
6:35
the benefits of bispecific antibodies for treating multiple myeloma
-
2:56
the exciting future of bispecific antibodies
-
11:27
distinguish malignant vs. benign lung nodules
-
3:15
what is the best diet for myeloma patients to build a strong immune system?
-
5:06
bispecific antibodies: late side effects
-
2:22
outcomes and management of patients with r/r myeloma who progress on bispecific antibodies
-
6:09
transforming therapy for patients with relapsed myeloma: the era of bispecific antibodies
-
2:33
the role of bispecific antibodies in the treatment of patients with multiple myeloma
-
7:05
developments in the use of bispecific antibodies in myeloma and challenges in this space
-
2:07
challenges associated with the management of extramedullary myeloma & ongoing research
-
1:29
bispecific bcma-cd3 antibody teclistamab is efficacious and tolerable in r/r mm
-
3:16
the optimization of induction chemotherapy for patients with aml
-
2:50
phase i study of abbv383, a novel bcmaxcd3 bispecific antibody, in r/r multiple myeloma
-
1:33
sequencing and the management of adverse events when administering bispecifics for myeloma
-
1:56
treatment selection & sequencing in patients with relapsed, intolerant, or refractory myeloma
-
1:50
real-world outcomes of teclistamab treatment in r/r multiple myeloma
-
2:42
enhancing outcomes in multiple myeloma with immune-based strategies
-
1:20
a comparison of bispecific antibodies emerging in multiple myeloma
-
1:38
the efficacy of cevostamab in r/r multiple myeloma and the importance of bispecific antibodies